Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans

被引：42
作者：
Etchart, Nathalie
Hennino, Ana
Friede, Martin
Dahel, Karima
Dupouy, Monique
Goujon-Henry, Catherine
Nicolas, Jean-Francois
Kaiserlian, Dominique
机构：
[1] INSERM, U 404, F-69007 Lyon, France
[2] Univ Lyon 1, F-69003 Lyon, France
[3] IFR 128, F-69007 Lyon, France
[4] INSERM, U503, F-69007 Lyon, France
[5] World Hlth Org Initiat Vaccine Res, CH-12211 Geneva, Switzerland
[6] Hosp Civ Lyon, Ctr Hosp Lyon Sud, Serv Immunol Clin Allergol, F-69495 Pierre Benite, France
来源：
VACCINE | 2007年 / 25卷 / 39-40期
关键词：
transcutaneous administration; measles virus; Vaccines; IgA;
D O I：
10.1016/j.vaccine.2007.07.014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Transcutaneous immunisation (TCI) using a skin patch is a non-invasive vaccination route relevant to mass vaccination against infectious diseases. This phase I/II clinical study, documents that TCI of human adult volunteers with the live-attenuated measles vaccine ROUVAX((R)) is safe and poorly reactogenic. It promotes induction of measles-specific salivary IgA and a tendency to increased frequency of NIV-specific IFN-gamma-producing T cells. However, in contrast to the subcutaneous route, TCI failed to evoke neutralising NIV-specific serum antibodies. Thus, alternative delivery methods and/or devices providing optimal uptake by skin DC should be considered for live-attenuated virus vaccines, such as the measles vaccine. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6891 / 6899
页数：9
相关论文
共 44 条
[1]   CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice [J].
Akiba, H ;
Satoh, M ;
Iwatsuki, K ;
Kaiserlian, D ;
Nicolas, JF ;
Kaneko, F .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (03) :488-493
[2]   Epidermal viral immunity induced by CD8α+ dendritic cells but not by Langerhans cells [J].
Allan, RS ;
Smith, CM ;
Belz, GT ;
van Lint, AL ;
Wakim, LM ;
Heath, WR ;
Carbone, FR .
SCIENCE, 2003, 301 (5641) :1925-1928
[3]   Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses [J].
Anjuère, F ;
George-Chandy, A ;
Audant, F ;
Rousseau, D ;
Holmgren, J ;
Czerkinsky, C .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1586-1592
[4]   Serum antibody responses after intradermal vaccination against influenza [J].
Belshe, RB ;
Newman, FK ;
Cannon, J ;
Duane, C ;
Treanor, J ;
Van Hoecke, C ;
Howe, BJ ;
Dubin, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (22) :2286-2294
[5]   Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia ankara vaccine against lethal poxvirus infection even in a CD4-deficient host [J].
Belyakov, Igor M. ;
Isakov, Dmitry ;
Zhu, Qing ;
Dzutsev, Amiran ;
Klinman, Dennis ;
Berzofsky, Jay A. .
JOURNAL OF IMMUNOLOGY, 2006, 177 (09) :6336-6343
[6]   Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells [J].
Belyakov, IM ;
Hammond, SA ;
Ahlers, JD ;
Glenn, GM ;
Berzofsky, JA .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (07) :998-1007
[7]   Progress on new vaccine strategies against chronic viral infections [J].
Berzofsky, JA ;
Ahlers, JD ;
Janik, J ;
Morris, J ;
Oh, S ;
Terabe, M ;
Belyakov, IM .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (04) :450-462
[8]   Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling [J].
Bieback, K ;
Lien, E ;
Klagge, IM ;
Avota, E ;
Schneider-Schaulies, J ;
Duprex, WP ;
Wagner, H ;
Kirschning, CJ ;
ter Meulen, V ;
Schneider-Schaulies, S .
JOURNAL OF VIROLOGY, 2002, 76 (17) :8729-8736
[9]   Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis [J].
Bynoe, MS ;
Evans, JT ;
Viret, C ;
Janeway, CA .
IMMUNITY, 2003, 19 (03) :317-328
[10]   Alternative routes of measles immunization: a review [J].
Cutts, FT ;
Clements, CJ ;
Bennett, JV .
BIOLOGICALS, 1997, 25 (03) :323-338
12345